Mark Barberio appointed Chairman of the Board of Directors effective at 2021 Annual General Meeting
DUBLIN, April 27, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo" or the "Company") today announced that Mark Barberio, who currently serves as an independent member of Endo's Board of Directors (the "Board"), has been appointed Chairman of the Board effective at the Company's 2021 Annual General Meeting. Mr. Barberio's appointment is part of Endo's ongoing Board succession process, which has also included adding two new Board members since the Company's 2020 Annual General Meeting. In addition, Paul Campanelli, who has served as Chairman of the Board since 2019 and who served as President and Chief Executive Officer from 2016 to 2020, will retire from the Board upon the expiration of his current term at the Company's 2021 Annual General Meeting. Finally, Roger Kimmel, who has been Senior Independent Director since 2019 and who served as Chairman of the Board from 2014 to 2019, will also retire from the Board upon the expiration of his current term.
"I am honored to have been appointed Chairman during this important period of Endo's transformation," said Mr. Barberio. "I have seen firsthand the Board and management team's commitment to taking the actions necessary to deliver sustainable value over the long-term. On behalf of the Board, I want to thank Paul and Roger for their many years of service and dedication to Endo. Their leadership, insights and perspectives have been invaluable as Endo has advanced its strategic priorities."
"Since joining the Board, Mark has provided valuable strategic perspectives and expertise. I look forward to working closely with him as we continue delivering life-enhancing products," said Blaise Coleman, President and Chief Executive Officer of Endo. "I also want to thank Roger for his many contributions during his years of service on the Board and Paul for his invaluable leadership and critical guidance."
Mr. Barberio has been a member of the Board since February 2020. He has been a Principal of Markapital, LLC since May 2013 and currently serves as a Director of Gibraltar Industries, Inc. and Life Storage, Inc., where he has been Non-Executive Chairman since May 2018.
About Endo
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the relevant Canadian securities legislation, including, but not limited to, the statements by Messrs. Barberio and Coleman and other statements regarding the Company and changes to the Board of Directors. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, and as otherwise enumerated herein or therein, could affect Endo's future results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in this communication. The forward-looking statements in this press release are qualified by these risk factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.
View original content to download multimedia:http://www.prnewswire.com/news-releases/endo-implements-board-succession-plan-301278384.html
SOURCE Endo International plc
Media: Heather Zoumas-Lubeski, (484) 216-6829; media.relations@endo.com, Investors: Pravesh Khandelwal, (845)-364-4833; relations.investor@endo.com
